TECP
MBX

Trails Edge Capital Partners’s MBX Biosciences MBX Stock Holding History

Trails Edge Capital Partners’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-315,158
Closed -$9.94M – 35
2025
Q4 		$9.94M Buy
+315,158
New +$7.65M 2.46% 18

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Trails Edge Capital Partners's MBX Position: Q1 2026 in Review

Trails Edge Capital Partners sold out of MBX Biosciences (MBX) in Q1 2026, closing a stake of 315,158 shares — an estimated $9.94M sold.

Trails Edge Capital Partners first reported a position in MBX in Q4 2025 and held it in 1 quarter. The position peaked at $9.94M in Q4 2025. 157 funds tracked by Wall St. Rank hold MBX as of Q1 2026.

  • Trails Edge Capital Partners reported no remaining MBX Biosciences position as of Q1 2026 after selling out during the quarter.
  • Trails Edge Capital Partners sold 315,158 MBX Biosciences shares in Q1 2026, an estimated $9.94M.
  • Trails Edge Capital Partners first reported a position in MBX Biosciences in Q4 2025 and held it in 1 quarter.
  • Trails Edge Capital Partners's MBX Biosciences position peaked at $9.94M in Q4 2025.
  • 157 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2026.

Based on Trails Edge Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.